Last updated: August 4, 2026
Carmustine is a mature, low-volume oncology drug with two distinct commercial markets: injectable carmustine for conditioning and salvage chemotherapy, and Gliadel, a biodegradable intracranial wafer used after resection of malignant glioma. The active ingredient has no meaningful remaining composition-patent protection in the United States. Commercial value now depends on sterile manufacturing, hospital procurement, regulatory status, supply reliability, and the differentiated delivery profile of Gliadel.
The injectable market is exposed to generic competition and periodic shortage risk. Gliadel has a more defensible commercial position because it is a combination of carmustine and a localized implant-delivery system, but its clinical use is narrow and competing glioblastoma treatments limit volume growth.
What products contain carmustine?
Carmustine, also known as BCNU, is a nitrosourea alkylating agent. FDA-approved products include injectable carmustine and the Gliadel implant.
| Product |
Dosage form |
Primary use |
U.S. regulatory status |
Commercial position |
| Carmustine for injection |
Sterile lyophilized powder for intravenous infusion |
Conditioning before autologous stem-cell transplantation; multiple myeloma and lymphoma regimens; selected brain tumors |
Generic and brand/generic injectable products |
Mature, price-sensitive hospital market |
| BiCNU |
Injectable carmustine |
Historical branded injectable presentation |
Legacy brand associated with NDA 016863 |
Brand identity has limited value against generic supply |
| Gliadel |
Polifeprosan 20 with carmustine implant |
Local treatment after resection of malignant glioma |
NDA 020637 |
Specialty neurosurgical product with higher differentiation |
| Generic carmustine implants or wafers |
No established broad U.S. generic market comparable to injectable carmustine |
Same localized delivery concept |
Limited competitive penetration |
Manufacturing and clinical-development barriers are higher |
The FDA approved carmustine injection in the 1970s. Gliadel received FDA approval in 1996 for intracranial implantation after surgical resection of malignant glioma [1,2].
When does carmustine lose exclusivity?
Carmustine’s core U.S. composition and use patents expired decades ago. The injectable product is therefore commercially exposed to generic competition rather than patent-based exclusivity.
| Exclusivity category |
Injectable carmustine |
Gliadel |
| New chemical entity exclusivity |
Expired |
Expired |
| Core composition patents |
Expired |
Expired or no longer commercially controlling |
| Injectable formulation protection |
Expired or commercially weak |
Not applicable |
| Delivery-system protection |
Not applicable |
Historical implant patents largely expired |
| Orphan-drug protection |
Not a primary current barrier |
Historical orphan designation does not create current market exclusivity |
| Biosimilar exclusivity |
Not applicable |
Not applicable |
| Current commercial barrier |
Sterile cytotoxic manufacturing and supply |
Implant manufacturing, clinical evidence, neurosurgical adoption and reimbursement |
The effective exclusivity period ended long before the current generic market formed. Any current commercial advantage must come from manufacturing capability, regulatory execution, supply contracts, physician familiarity or the technical complexity of the Gliadel wafer.
What patents protect carmustine and Gliadel?
The principal carmustine molecule is old and does not support a modern patent moat. Historical protection around Gliadel focused on the biodegradable polymer matrix, localized release and implant construction rather than on carmustine itself.
The relevant intellectual-property categories are:
- The polifeprosan 20 polymer matrix.
- Controlled release of carmustine from the implant.
- Wafer geometry, handling and implantation.
- Manufacturing processes for incorporating carmustine into the polymer.
- Method-of-use claims involving implantation after tumor resection.
The commercial importance of these patents has declined as the underlying patent families reached expiration. A new entrant would still face technical and regulatory barriers because an intracranial carmustine implant requires reproducible drug loading, release kinetics, sterility, mechanical integrity and surgical usability. Those barriers are regulatory and manufacturing barriers, not strong current exclusivity rights.
The FDA Orange Book remains the relevant source for current listed patents and regulatory exclusivity. For mature products such as carmustine injection, the absence of active listed patents means an ANDA applicant can generally pursue approval without waiting for a meaningful patent cliff [3].
What is the FDA regulatory status of carmustine?
Carmustine injection is an approved small-molecule oncology drug. Gliadel is regulated as a drug product with a specialized implant dosage form. The FDA-approved labels identify different dosing, handling and safety requirements.
Carmustine injection is administered intravenously and requires preparation in a controlled setting. The drug is highly toxic, chemically reactive and subject to dose-limiting myelosuppression. Pulmonary toxicity, renal toxicity and delayed marrow suppression affect treatment selection and monitoring [1].
Gliadel is placed into the surgical cavity following tumor resection. Its value proposition is local delivery of carmustine while reducing reliance on systemic exposure. The product does not eliminate the need for radiation or systemic therapy in the broader glioblastoma treatment pathway. The label includes warnings concerning seizures, cerebral edema, wound-healing complications, infection and other neurosurgical risks [2].
How large is the carmustine market?
Carmustine is a niche oncology market by unit volume. It is not comparable with large hematology or solid-tumor products such as lenalidomide, temozolomide or bevacizumab.
The market has four structural characteristics:
- Low patient volume relative to mainstream oncology drugs.
- High clinical value in selected transplant and salvage protocols.
- Limited brand loyalty for injectable carmustine.
- Disproportionate pricing sensitivity to manufacturing interruptions.
Public company filings generally do not report U.S. carmustine revenue as a separate line item. Revenue exposure is usually embedded in broader specialty-pharmaceutical or hospital-product segments. This limits the reliability of market-size estimates based only on issuer disclosures.
The injectable product can command high transaction prices despite an old active ingredient because sterile oncology manufacturing is expensive and supplier competition is limited. Price increases in mature sterile injectables often reflect supply concentration, capacity constraints, raw-material problems or quality-related shutdowns rather than new clinical value.
Gliadel has a different revenue profile. It is a higher-value product per procedure, but its addressable market is restricted by the number of malignant glioma resections, surgeon adoption, treatment guidelines and reimbursement. The product’s sales ceiling is therefore determined by procedure volume rather than by the much larger population of patients with cancer.
What drives carmustine demand?
Stem-cell transplantation
Carmustine remains relevant in conditioning regimens for autologous hematopoietic stem-cell transplantation, particularly in multiple myeloma and lymphoma treatment. Regimen selection varies by institution and disease setting. Melphalan and multi-agent conditioning approaches compete with carmustine in different indications.
Lymphoma and salvage therapy
Carmustine has historical use in combination regimens for Hodgkin lymphoma and non-Hodgkin lymphoma. Modern antibody-drug conjugates, cellular therapies, targeted agents and checkpoint inhibitors have reduced the relative importance of older salvage chemotherapy in some settings.
Primary brain tumors
Systemic carmustine competes with temozolomide and other therapies. Gliadel offers a localized alternative after resection, but its use is constrained by surgical eligibility and concerns about postoperative complications.
Treatment guidelines and institutional protocols
Hospital protocols have a direct effect on volume. A change in transplant conditioning preference can shift demand quickly because the product is used in concentrated specialty settings rather than through broad retail prescribing.
How strong is the carmustine patent estate?
The injectable carmustine patent estate is weak from a blocking perspective. The active ingredient is old, the product has long-standing generic competition and current value is not based on exclusivity.
Gliadel has a stronger product-differentiation position but not a durable patent moat. Its defensibility rests on:
- Complex implant manufacturing.
- Drug-polymer compatibility.
- Release-rate control.
- Sterility and stability requirements.
- Surgical workflow integration.
- Clinical familiarity.
- Regulatory cost for a competing implant.
- Reimbursement and hospital formulary acceptance.
This distinction matters for investment analysis. A competitor may face a demanding development program even when it does not face a strong patent barrier. Conversely, the incumbent cannot rely on expired patents to prevent competition once a technically credible competitor receives approval.
Are there Paragraph IV challenges to carmustine?
Paragraph IV risk is more relevant to any newly filed or reformulated carmustine product than to the original injectable drug.
For standard injectable carmustine, the practical risk is ordinary ANDA competition against an old product, subject to FDA requirements for bioequivalence, sterile manufacturing and product quality. The remaining patent landscape does not create a clear basis for prolonged Hatch-Waxman exclusivity.
For Gliadel, an ANDA pathway would be more complex because the product is an implant with a polymer matrix and localized release profile. A competing applicant could face questions involving equivalence of drug loading, release kinetics, mechanical properties, implantation and clinical performance. The key risk is regulatory complexity rather than a conventional Paragraph IV patent battle.
The FDA Orange Book should be reviewed for any current patent listings tied to the relevant NDA before assessing a specific launch. Historic patents associated with carmustine or the Gliadel delivery system should not be treated as live barriers without confirmation of their expiration and listing status [3].
Which companies are challenging the carmustine market?
Competition is fragmented. The injectable market includes generic manufacturers and specialty suppliers rather than a single dominant global challenger. Competitive positioning depends on:
- FDA-approved manufacturing capacity.
- Reliable supply of sterile vials.
- Ability to manage hazardous-drug production.
- Hospital contracting.
- Wholesale-distributor access.
- Pricing discipline during shortages.
Gliadel competition is more limited because a substitute must reproduce the clinical and operational role of an intracranial implant. The main competitive threat is not necessarily another carmustine wafer. It is the broader treatment landscape, including temozolomide, radiation, tumor-treating fields, bevacizumab, clinical trials and repeat-surgery strategies.
What patent litigation and settlement agreements affect carmustine?
Carmustine is not associated with a current, widely reported patent dispute comparable with litigation around high-revenue specialty drugs. The principal litigation risk is product liability, manufacturing quality, labeling or regulatory compliance rather than an active molecule patent conflict.
No major settlement-driven generic launch framework is central to the current carmustine market. The absence of a settlement does not mean the market is free of launch risk. A generic supplier can still be delayed by manufacturing deficiencies, FDA review, inspection findings, supply problems or limited commercial economics.
What is the competitive outlook versus temozolomide?
| Factor |
Carmustine |
Temozolomide |
| Core status |
Mature generic cytotoxic |
Mature generic alkylating agent |
| Main administration |
IV or intracranial implant |
Oral capsules and injectable formulation |
| Convenience |
Lower for IV therapy; surgical for Gliadel |
Higher for oral therapy |
| Patent strength |
Minimal for core product |
Minimal for core product |
| Primary demand driver |
Transplant conditioning, salvage therapy, selected glioma use |
Broad glioma treatment protocols |
| Manufacturing risk |
High for sterile injectable and wafer |
Lower for oral solid dosage |
| Market breadth |
Narrow |
Broader neuro-oncology use |
| Generic competition |
Established for injection |
Established and extensive |
Temozolomide has broader routine use in glioblastoma, while carmustine retains value in selected treatment settings and as a local implant. The products are not fully interchangeable because they differ in administration, treatment timing and clinical role.
What generic entry risks exist for carmustine?
The most credible generic-entry scenario is continued competition in injectable carmustine. The principal risks to incumbent economics are:
- Additional sterile-injectable suppliers entering after FDA approval.
- Hospital tenders replacing brand or higher-priced suppliers.
- Contracting pressure from group purchasing organizations.
- Substitution toward alternative conditioning or salvage regimens.
- Supply normalization after shortage periods.
- Reduced reimbursement margins for hospitals.
Gliadel faces a slower but potentially more disruptive entry scenario. A competing implant could take market share without needing to undercut injectable carmustine directly. Its development burden would be higher, but an approved alternative could pressure price and hospital contracting.
How does carmustine generate revenue?
Carmustine revenue is driven by volume, unit price and supply continuity. Because the product is old, revenue growth cannot be sustained by expanding a protected indication in the same way as a newly launched oncology therapy.
| Revenue driver |
Injectable carmustine |
Gliadel |
| Volume growth |
Transplant activity and protocol use |
Malignant glioma resection volume |
| Price growth |
Limited by generic competition, but vulnerable to shortages |
More possible because of product differentiation |
| Gross-margin support |
Sterile manufacturing scarcity |
Complex implant manufacturing |
| Commercial risk |
Generic price erosion and supply disruption |
Narrow clinical market and procedure dependence |
| Long-term outlook |
Stable to declining in normalized pricing |
Niche, with modest growth potential if adoption expands |
A producer with excess sterile capacity may find carmustine strategically useful despite limited absolute sales. The drug can occupy manufacturing slots, support hospital relationships and provide revenue during periods when competitors experience shortages. For a branded specialty company, the product is more likely to be a portfolio stabilizer than a major growth asset.
What is the geographic market coverage?
The United States remains the most commercially significant market because of high oncology pricing and a structured generic approval system. Europe, Japan and other regulated markets also use carmustine, but prices, procurement rules and reimbursement differ substantially.
Geographic barriers include:
- Separate marketing authorizations.
- Country-specific reimbursement.
- Cytotoxic handling requirements.
- Local sterile-manufacturing standards.
- Different transplant protocols.
- Hospital tender systems.
- Import and supply-chain controls.
Gliadel has a smaller global addressable market than injectable carmustine because it requires neurosurgical adoption and reimbursement for an implant procedure. Geographic expansion depends more on center-level adoption than on broad prescription promotion.
Key Takeaways
- Carmustine is a mature, low-volume oncology drug with limited patent-based exclusivity.
- Injectable carmustine is primarily a generic sterile-injectable market.
- Gliadel has greater product differentiation but remains a narrow neurosurgical product.
- Core composition patents and historical formulation protection are expired or commercially weak.
- Current barriers are manufacturing quality, sterile capacity, implant technology, reimbursement and clinical adoption.
- Biosimilar risk is irrelevant because carmustine is a small molecule, not a biologic.
- Paragraph IV litigation is not the central market issue; ordinary generic entry and supply reliability matter more.
- Public company filings generally do not disclose carmustine revenue separately.
- Revenue is likely to remain stable or decline for injectable products under normalized generic competition.
- Gliadel has higher revenue per procedure but a smaller and clinically constrained market.
FAQs About Carmustine Market and Patent Risk
Is carmustine still under patent protection?
The core carmustine molecule and historical injectable-product rights are not protected by meaningful current U.S. exclusivity. Specific patents covering a later formulation or delivery system must be checked separately.
Is Gliadel a generic drug?
Gliadel is an FDA-approved implant product, not a conventional generic injectable. Its polymer matrix, drug-release properties and surgical administration make direct substitution more complex.
Can a company launch a generic carmustine injection?
Yes. The commercial pathway is an ANDA, subject to FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, sterility, stability and manufacturing quality.
Does carmustine have biosimilar competition?
No. Biosimilar law applies to biological products. Carmustine is a chemically synthesized small-molecule drug.
What is the largest commercial threat to Gliadel?
The largest threat is broader clinical substitution in malignant glioma, including systemic therapy, radiation, repeat surgery and emerging neuro-oncology treatments, rather than a single competing carmustine patent.
References
- U.S. Food and Drug Administration. (n.d.). Carmustine for injection prescribing information. FDA. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Gliadel wafer prescribing information. FDA. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
- National Cancer Institute. (n.d.). Carmustine. National Cancer Institute. https://www.cancer.gov
- National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Central nervous system cancers. NCCN. https://www.nccn.org
- National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Multiple myeloma. NCCN. https://www.nccn.org
